Study of ARCT-810 for people with OTC deficiency
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests an experimental medicine called ARCT-810 for people with Ornithine Transcarbamylase (OTC) deficiency, a condition that affects the liver's ability to remove ammonia from the body. The study aims to see if ARCT-810 can help lower ammonia levels safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You have been diagnosed with OTC deficiency by a doctor.
- You have had symptoms of high ammonia in the past, but your condition has been stable for at least one month.
- You are on a stable treatment plan (diet, supplements, or medicines) for at least 28 days.
- You have not received gene therapy or stem cell therapy for OTC in the past 2 years.
- You do not have a history of organ transplant, cancer (except treated skin cancer), or certain heart or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy called ECUR-506 for baby boys under 9 months old with a severe form of OTC deficiency. The goal is to see if it can help their bodies process ammonia better, reducing the need for a strict protein-restricted diet and medications.
This early-phase study tests an AAV gene therapy meant to reduce ammonia levels in children with ornithine transcarbamylase (OTC) deficiency. It’s designed to slow or stop ammonia-related harm, while also carefully monitoring safety for years.
This study uses MRI scans and memory/thinking tests to understand brain effects of urea cycle disorders, like ornithine transcarbamylase deficiency (OTCD) and argininosuccinate (ASSD/ASLD). It may help researchers understand how brain function changes during and between metabolic crises.
This trial tests a new medicine called LNP.UCD.ABE that aims to fix a specific genetic change causing a severe urea cycle disorder. It uses a technique called base editing to correct the gene mutation, which may help your body break down ammonia better.
This study tests a new medicine called KRRO-121 in healthy people first, and then in patients with urea cycle disorders, to see if it is safe and how well it works. The goal is to find a new way to manage this condition.
This trial tests a device for measuring ammonia levels at home in people with rare metabolic conditions that cause high ammonia. It aims to make monitoring easier and more convenient for patients.
Hear when a new Ornithine Transcarbamylase Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.